| Daniel Cavalcante, MD | |
|
12605 E 16th Ave, Aurora, CO 80045-2545 | |
| (720) 848-0000 | |
| Not Available |
| Full Name | Daniel Cavalcante |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 9 Years |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356758692 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | FE60437232 (Washington) | Secondary |
| 207T00000X | Neurological Surgery | 59615 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boulder Community Health | Boulder, CO | Hospital |
| Longs Peak Hospital | Longmont, CO | Hospital |
| Medical Center Of The Rockies | Loveland, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, announced today that it has received full accreditation from the URAC Accreditation Committee for its mail-service pharmacy, PrimeMail®.
Scientists are reporting development of a new use for magnetic levitation, or "maglev," the futuristic technology best known for enabling high-speed passenger trains to float above the tracks. In ACS' bi-weekly Journal of Agricultural and Food Chemistry, they describe putting maglev to use in an inexpensive sensor for analyzing food, water, and other beverages.
The state media in China has reported that in the northeast of the country anthrax has killed one person and infected 12 more.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.
› Verified 9 days ago
| Entity Name | Denver Health And Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, announced today that it has received full accreditation from the URAC Accreditation Committee for its mail-service pharmacy, PrimeMail®.
Scientists are reporting development of a new use for magnetic levitation, or "maglev," the futuristic technology best known for enabling high-speed passenger trains to float above the tracks. In ACS' bi-weekly Journal of Agricultural and Food Chemistry, they describe putting maglev to use in an inexpensive sensor for analyzing food, water, and other beverages.
The state media in China has reported that in the northeast of the country anthrax has killed one person and infected 12 more.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.
› Verified 9 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, announced today that it has received full accreditation from the URAC Accreditation Committee for its mail-service pharmacy, PrimeMail®.
Scientists are reporting development of a new use for magnetic levitation, or "maglev," the futuristic technology best known for enabling high-speed passenger trains to float above the tracks. In ACS' bi-weekly Journal of Agricultural and Food Chemistry, they describe putting maglev to use in an inexpensive sensor for analyzing food, water, and other beverages.
The state media in China has reported that in the northeast of the country anthrax has killed one person and infected 12 more.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Cavalcante, MD Po Box 110429, Aurora, CO 80042-0429 Ph: () - | Daniel Cavalcante, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Prime Therapeutics LLC (Prime), a thought leader in pharmacy benefit management, announced today that it has received full accreditation from the URAC Accreditation Committee for its mail-service pharmacy, PrimeMail®.
Scientists are reporting development of a new use for magnetic levitation, or "maglev," the futuristic technology best known for enabling high-speed passenger trains to float above the tracks. In ACS' bi-weekly Journal of Agricultural and Food Chemistry, they describe putting maglev to use in an inexpensive sensor for analyzing food, water, and other beverages.
The state media in China has reported that in the northeast of the country anthrax has killed one person and infected 12 more.
Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."
New research to be published in tomorrow's issue of the Journal of the American Medical Association (JAMA) (Vol. 302, No. 11), by a team at The Cancer Institute of New Jersey (CINJ), shows that men diagnosed with prostate cancer beginning in the early 1990's had significantly improved survival outcomes compared with patients whose cancers were diagnosed in prior decades.
› Verified 9 days ago
James Kelly, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Dr. Yasunori Nagahama, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Kevin Ess, MD, PHD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Michael Finn, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Christopher D Roark, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 Fax: 734-936-9294 | |
Dr. Jason Weedman, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 303-724-2302 | |
Dr. Daniel R Kramer, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |